| Literature DB >> 29679612 |
Pengyu Jing1, Nan Zhao2, Mingxiang Ye3, Yong Zhang3, Zhipei Zhang4, Jianyong Sun4, Zhengxin Wang5, Jian Zhang6, Zhongping Gu7.
Abstract
Protein arginine methyltransferase 5 (PRMT5) functions as a tumor initiator to regulate several cancer progressions, such as proliferation and apoptosis, by catalyzing the symmetrical dimethylation (me2s) of arginine residues within targeted molecules. However, the exact role of PRMT5-mediated metastasis in lung cancer is not fully understood. Here, we illustrated its potential effects in lung cancer metastasis in vivo and vitro. PRMT5 was frequently overexpressed in lung tumors, and its expression was positively related to tumor stages, lymphatic metastasis and poor outcome. In this model, PRMT5 repressed the transcription of the miR-99 family by symmetrical dimethylation of histone H4R3, which increased FGFR3 expression and in turn activated Erk1/2 and Akt, leading to cell growth and metastasis in lung cancer. Furthermore, loss of PRMT5 exerted anti-metastasis effects on lung cancer progression by blocking histone-modification of miR-99 family. Overall, this study provides new insights into the PRMT5/miR-99 family/FGFR3 axis in regulating lung cancer progression and identifies PRMT5 as a promising prognostic biomarker and therapeutic target.Entities:
Keywords: FGFR3; H4R3me2s; Lung cancer; PRMT5; Tumor progression; miR-99 family
Mesh:
Substances:
Year: 2018 PMID: 29679612 DOI: 10.1016/j.canlet.2018.04.019
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679